Filtered By:
Specialty: Rheumatology
Condition: Arthritis
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 260 results found since Jan 2013.
Benefits of Methotrexate Use on Cardiovascular Disease Risk among Rheumatoid Arthritis Patients Initiating Biologic Disease-Modifying Antirheumatic Drugs.
CONCLUSION: Among RA patients receiving biologics, concomitant methotrexate use was associated with a 24% lower risk for CVD events.
PMID: 33060309 [PubMed - as supplied by publisher]
Source: J Rheumatol - October 15, 2020 Category: Rheumatology Authors: Xie F, Chen L, Yun H, Levitan EB, Curtis JR Tags: J Rheumatol Source Type: research
Cardiovascular morbidity and mortality in patients with spondyloarthritis: A meta ‐analysis
ConclusionsOur meta ‐analysis demonstrated that patients with SpA have a significantly increased risks of MI and stroke, but without a significant increase in the all‐cause mortality, than that in the general population. The higher risk of CV in patients with SpA than that in the general population indicates the ne ed for strict risk factor correction and disease management.
Source: International Journal of Rheumatic Diseases - September 24, 2020 Category: Rheumatology Authors: Ji Hyoun Kim,
In Ah Choi Tags: ORIGINAL ARTICLE Source Type: research
O27 Frailty and co-morbidity in people with osteoarthritis and rheumatoid arthritis
Conclusion Co-morbidity is associated with an increased occurrence of pre-frailty and frailty among people with OA and RA and interacts synergistically with OA and RA to increase the likelihood of pre-frailty and frailty.Disclosure M.J. Cook: None.M. Lunt: None.S.M.M. Verstappen: None.T.W. O'Neill: None.
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry
The objective of this study is to examine the possibility of a relationship between subcutaneous nodules and “first ever” cardiovascular disease event, i.e., myocardial infarction (MI), stroke, or cardiovascular death in a large registry-cohort of patients with RA. Patient information was collected from the CORRONA registry from October 2001 to September 2011. A total of 26,042 patients with RA were studied for the presence or absence of subcutaneous nodules. Cox proportional hazards regression models were constructed to estimate the hazard ratios (HR) for CVD events in relation to subcutaneous nodules at baseline. Thr...
Source: Clinical Rheumatology - August 4, 2015 Category: Rheumatology Source Type: research
Does renin‐angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case‐control study
Conclusions: Our data do not support the hypothesis that ACEIs/ARBs may be protective against atherosclerotic CVEs in LN patients. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - February 11, 2016 Category: Rheumatology Authors: Konstantinos Tselios, Dafna D Gladman, Jiandong Su, Murray B Urowitz Tags: Original Article Source Type: research
Rheumatoid Factors Are Associated with Subclinical and Clinical Atherosclerosis in African American Women: The Multi‐Ethnic Study of Atherosclerosis (MESA)
Conclusion. RA‐related autoantibodies are associated with subclinical and clinical atherosclerosis in AA women from a community based non‐RA cohort indicating autoimmune factors may play a role in the pathogenesis of atherosclerosis. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - May 8, 2016 Category: Rheumatology Authors: Darcy S. Majka, Thanh‐Huyen T. Vu, Richard M. Pope, Marius Teodorescu, Elizabeth W. Karlson, Kiang Liu, Rowland W. Chang Tags: Original Article Source Type: research
Does Renin ‐Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case–Control Study
ConclusionOur data do not support the hypothesis that ACE inhibitors/ARBs may be protective against atherosclerotic CVEs in LN patients.
Source: Arthritis Care and Research - August 18, 2016 Category: Rheumatology Authors: Konstantinos Tselios, Dafna D. Gladman, Jiandong Su, Murray B. Urowitz Tags: Original Article Source Type: research
Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study
AbstractThe aim of the study was to investigate the longitudinal transition trajectory of gout and its comorbidities in male patients with gout in different age groups. A total of 3973 male patients who received a new diagnosis of gouty arthritis were identified from the Taiwan Longitudinal Health Insurance Database and divided into two age cohorts (<50 and ≥50 years). Each patient was individually followed from 2000 to 2009 to identify associated comorbidities, namely hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular diseases, and chronic kidney disease. Two outcome measurements of stroke and all...
Source: Rheumatology International - December 20, 2016 Category: Rheumatology Source Type: research
Association of Rheumatoid Factors With Subclinical and Clinical Atherosclerosis in African American Women: The Multiethnic Study of Atherosclerosis
ConclusionRA‐related autoantibodies are associated with subclinical and clinical atherosclerosis in African American women from a community‐based non‐RA cohort, indicating autoimmune factors may play a role in the pathogenesis of atherosclerosis.
Source: Arthritis Care and Research - January 26, 2017 Category: Rheumatology Authors: Darcy S. Majka, Thanh ‐Huyen T. Vu, Richard M. Pope, Marius Teodorescu, Elizabeth W. Karlson, Kiang Liu, Rowland W. Chang Tags: Rheumatoid Arthritis Source Type: research
Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN.
PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - January 6, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes?
ConclusionFindings from the present study suggest that while CVD risk in RA is elevated, it is lower in magnitude compared to the CVD risk associated with diabetes. It therefore may not be appropriate to consider RA a diabetes risk‐equivalent with respect to hyperlipidemia management.This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - February 6, 2018 Category: Rheumatology Authors: Jeffrey R Curtis, Shuo Yang, Jasvinder A. Singh, Fenglong Xie, Lang Chen, Huifeng Yun, Paul Muntner, Shia T Kent, Emily B. Levitan, Monika M. Safford, Kenneth G. Saag, Jie Zhang Tags: Brief Report Source Type: research
Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
CONCLUSION: In this large cohort of publicly or privately insured patients with RA in the United States, ABA was associated with a 20% reduced risk of CVD versus TNFi. While this observational study is subject to potential residual confounding, our results were consistent in patients with baseline CVD.
PMID: 29764964 [PubMed - as supplied by publisher]
Source: J Rheumatol - May 15, 2018 Category: Rheumatology Authors: Jin Y, Kang EH, Brill G, Desai RJ, Kim SC Tags: J Rheumatol Source Type: research
Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents
Publication date: Available online 27 February 2019Source: Best Practice & Research Clinical RheumatologyAuthor(s): Fabiola Atzeni, Rossella Talotta, Ignazio Francesco Masala, Maria Chiara Gerardi, Roberto Casale, Piercarlo Sarzi-PuttiniAbstractCentral nervous system (CNS) involvement is quite unusual in patients with rheumatoid arthritis (RA), although cerebral vasculitis, rheumatoid nodules and meningitis have all been reported, and patients with RA may also have CNS comorbidities such as stroke and neuro-degenerative and demyelinating syndromes. It has been found that biological drugs, especially anti-tumour necrosis fa...
Source: Best Practice and Research Clinical Rheumatology - February 28, 2019 Category: Rheumatology Source Type: research
Antiphospholipid Syndrome is still a rare disease: the estimated prevalence in Piedmont and Aosta Valley
AbstractWe read with interest the recent article by Duarte ‐García, A. et al. where they reported an estimated prevalence of the antiphospholipid syndrome (APS) of 50 cases per 100,000 population. APS is an autoimmune disorder characterized by thrombotic events, pregnancy morbidity, or both in the presence of persistent positivity for antiphospholipid an tibodies (aPL). While APS is often held as the most common acquired thrombophilia, the global incidence and the prevalence of APS in the general population still need to be fully elucidated. Some reports estimate an incidence of 5 cases per 100,000 persons per year and ...
Source: Arthritis and Rheumatology - June 16, 2020 Category: Rheumatology Authors: Massimo Radin, Savino Sciascia, Mario Bazzan, Tiziana Bertero, Renato Carignola, Barbara Montaruli, Antonella Vaccarino, Erika Montabone, Irene Cecchi, Elena Rubini, Dario Roccatello, Simone Baldovino, on behalf of the Piedmont, Aosta Valley APS Consortiu Tags: LETTER TO THE EDITOR Source Type: research
